CROHN’S DISEASE
RHB 104 (anti-microbial therapy)
• Oral: clarithromycin, rifabutin, & clofazamine vs. placebo
• Current treatment with 5-ASA, corticosteroids, immunomodulators or infliximab or adalimumab with active symptoms

CROHN’S OR ULCERATIVE COLITIS
Adalimumab: high vs. standard dose induction
• Subcutaneous; high dose induction vs. standard dose
• Prior biologics not allowed except infliximab
• Current other stable IBD therapies allowed
• Concurrent or prior treatment with a full and adequate course of corticosteroids or immunomodulators

CROHN’S OR ULCERATIVE COLITIS
Etrolizumab (anti-α4β7 / αEβ7 integrin antibody)
• Subcutaneous; placebo-controlled
• Off anti-TNF at least 8 weeks
• Prior vedolizumab or natalizumab not allowed
• Crohn’s: failed/intolerant to corticosteroids, immunomodulators, or anti-TNF therapies within 5 years from screening
• UC: anti-TNF failure

CROHN’S DISEASE
MEDI-2070 (fully human monoclonal antibody/ inhibits IL-23)
• IV and subcutaneous, placebo-controlled
• Failed or intolerant to at least one anti-TNF
• Current other stable IBD therapies allowed
• Off Anti-TNFs and Vedolizumab for 5 half-lives

CROHN’S DISEASE
Mongersen /GED-0301 (anti- Smad7 therapy)
• Oral; placebo-controlled
• Failed/intolerant to aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants or biologics
• Off biologics for 8 weeks

ULCERATIVE COLITIS
Etrolizumab vs. Adalimumab vs. Placebo
• Subcutaneous; anti-α4β7 / αEβ7 integrin vs. anti-TNF
• Biologic naïve
• Failed or intolerant to prior immunosuppressant treatments

ULCERATIVE COLITIS
Apremilast (inhibitor of phosphodiesterase 4)
• Oral; placebo-controlled
• Biologic naïve
• Failed/intolerant to at least one of the following: 5-ASA compounds, corticosteroids, or immunosuppressants

ULCERATIVE COLITIS
RPC1063 (oral S1P receptor modulator)
• Oral; placebo-controlled
• Current treatment with oral aminosalicylates, prednisone, or budesonide
• Off biologics 5+ half lives

ULCERATIVE COLITIS
LY3074828 (humanized monoclonal antibody/ inhibits IL-23)
• IV and Subcutaneous; placebo-controlled
• Biologic naïve/failed/intolerant to one or more biologics
• Off anti-TNF 8+ weeks/off vedolizumab 12+ weeks

ULCERATIVE COLITIS
Lycera/ LYC-30937-EC (allosteric modulator targeting the mitochondrial ATP synthase, the F1F0-ATPase)
• Oral; placebo-controlled
• Currently receiving oral aminosalicylates or prednisone
• Off biologics for 12 weeks

Contact us before starting the next drug!
Contact us before scoping the patient!